Stay Updated
For all press requests, please reach out to [email protected].
News and Reports
Outside voices are divided. “Drugmakers have secured carveouts that dramatically shrink the reach of GLOBE,” said Merith Basey, CEO of Patients For Affordable Drugs. Sally C. Pipes of the Pacific Research Institute said the model “sets a dangerous precedent of importing foreign drug price controls into the United States.”
News and Reports
Healthcare Finance: Final GLOBE drug model saves less money than originally proposed
Merith Basey, CEO of Patients For Affordable Drugs said, “Drugmakers have secured carveouts that dramatically shrink the reach of GLOBE, while patients on Medicare Part B can still face 20% coinsurance for some of the most expensive drugs administered in a doctor’s office with no annual out-of-pocket cap that protects them from these costs.”
News and Reports
USA Today: The typical new drug costs $250K per year. Why prices march higher
Still, drug pricing watchdogs not involved in the study said six-figure prices for new drugs show the need to pressure pharmaceutical companies to lower prices. “This is exactly why we need to be negotiating on behalf of patients and taxpayers,” said Merith Basey, CEO of Patients For Affordable Drugs, a patient advocacy group. “This is […]
News and Reports
Consumer groups, meanwhile, are saying, “Told ya so.” “We warned that allowing drug companies to use voluntary deals to escape a mandatory pricing model would weaken GLOBE and reduce savings for patients. They moved forward anyway, and now we’re seeing the result,” said Merith Basey, CEO of Patients For Affordable Drugs, a patient advocacy group.
Press Releases
Administration Guts Mandatory GLOBE Drug Pricing Model With Pharma Carveouts
P4AD warned exemptions would weaken GLOBE; projected savings fall 96% from $11.9 billion to just $440 million WASHINGTON, D.C. — The Trump administration has finalized GLOBE, a mandatory Medicare Part B drug pricing model set to begin in early 2027, but the final model is now projected to save just $440 million — a staggering […]
News and Reports
Managed Healthcare Executive: Tariffs on patented drugs now apply to all branded drugmakers
Patient advocates have warned about the effect on costs and access. “Tariffs of this magnitude could have enormous consequences — raising costs, worsening shortages, and putting access to lifesaving medicines at risk,” Merith Basey, CEO of Patients for Affordable Drugs (P4AD), said in a statement.
Press Releases
56 Members of Congress Side With Big Pharma in Push to Weaken Medicare Negotiation
P4AD calls on CMS to stand firm against efforts to undermine Medicare’s power to negotiate lower drug prices WASHINGTON, D.C. — Patients For Affordable Drugs is calling on the Centers for Medicare & Medicaid Services (CMS) to stand firm against efforts to weaken Medicare Drug Price Negotiation after 56 members of Congress signed a letter […]
News and Reports
CareTalk with Laura Packard: Big Pharma Loses Again! But Will Trump's Deals Lower Your Drug Prices?
Big Pharma just lost again in court, but will your drug prices actually go down? On this episode of #CareTalk, I’m joined by Merith Basey from @patientsforaffordabledrugs for an update on the Medicare drug price negotiation lawsuits, Trump’s Most Favored Nation deals with drug manufacturers, and what it all means for patients. A federal appeals […]